



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/681,746		
		Filing Date	October 8, 2003		
		First Named Inventor	Thomas J.F. Nieland		
		Group Art Unit			
		Examiner Name			
Sheet	1	of	5	Attorney Docket Number	MIT 9952

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
W		3,625,214		Higuchi et al.	12-07-1971	
W		4,789,734		Pierschbacher	12-06-1988	
W		4,906,474		Langer et al.	03-06-1990	
W		4,925,673		Steiner et al.	05-15-1990	
W		5,925,333		Krieger et al.	07-20-1999	
W		5,962,322		Kozarsky et al.	10-05-1999	
W		6,121,319		Sommers	09-19-2000	
W		6,350,859		Krieger et al.	02-26-2002	
W		6,429,289		Krieger et al.	08-06-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
W		PCT	WO 96/00288		Mass. Inst. Tech.	01-04-1996		
W		PCT	WO 99/11288		Mass. Inst. Tech.	03-11-1999		

Examine Signature	V. Balasubramanian	Date Considered	2/6/06
-------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/681,746		
		Filing Date	October 8, 2003		
		First Named Inventor	Thomas J.F. Nieland		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	5	Attorney Docket Number	MIT 9952

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
M		ACTON, et al., "Expression cloning of SR-BI, a CD36-related class B scavenger receptor," <i>J. Biol. Chem.</i> 269:21003-21009 (1994).	
M		ACTON, et al., "Identification of Scavenger receptors SR-BI as a high density lipoprotein receptor," <i>Science</i> 271:518-520 (1996).	
M		ARAI, et al., "Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene," <i>J. Biol. Chem.</i> 274:2366-2371 (1999).	
M		BALDINI, et al., "Cloning of a Rab3 Isoform Predominately Expressed in Adipocytes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89: 5049-5052 (1992).	
M		BRAUN, et al., "Loss of SR-BI expression leads to early onset of occlusive atherosclerosis coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice," <i>Cir. Res.</i> 90: 270- 276 (2002).	
M		BROWN & GOLDSTEIN, "A receptor-mediated pathway for cholesterol homeostasis," <i>Science</i> 232: 34-47 (1986).	
M		CHARRON, et al., "A Glucose Transport Protein Expressed Predominately in Insulin-responsive Tissues," <i>Proc. Natl. Acad. Sci. USA</i> 86: 2535-2539 (1989).	
UP		FREEMAN, et al., "Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 88:4931-4935 (1991).	
Hy		GLASS, et al., "Dissociation of tissue uptake of cholesterol ester from that of apolipoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad," <i>Proc. Natl. Acad. Sci. USA</i> 80:5435-5439 (1983).	
M		GLASS, et al., "Uptake of high-density lipoprotein-associated apo-protein A-I and cholesterol esters by 16 tissues of the rat <i>in vivo</i> and by adrenal cells and hepatocytes <i>in vitro</i> ," <i>J. Biol. Chem.</i> 260:744-750 (1985).	

Examiner's Signature	V. Balasubramanian	Date Considered	2/6/06
----------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/681,746		
		Filing Date	October 8, 2003		
		First Named Inventor	Thomas J.F. Nieland		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	5	Attorney Docket Number	MIT 9952

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
M		GREGORIADIS, "Liposomes" in <i>Drug Carriers in Biology and Medicine</i> Chapter 14 pp. 287-341 (Academic Press, 1979).	
M		GU, et al., "Scavenger receptor class B, type I-mediated [³ H] cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor," <i>J. Biol. Chem.</i> 275: 29993-30001 (2000).	
M		GU, et al., "The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain," <i>J. Biol. Chem.</i> 273:26338-26348 (1998).	
G		HOLM, et al., "Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI," <i>Blood</i> 99: 1817-1824 (2002).	
M		HUNT & CALDERWOOD, "Characterization and sequence of a mouse hsp70 gene and its expression in mouse cell lines", <i>Gene</i> 87: 199-204 (1990).	
CL		INABA, et al., "Macrophage Colony-stimulating Factor Regulates Both Activities of Neutral and Acidic Cholesteryl Ester Hydrolases in Human Monocyte-derived Macrophages," <i>J. Clin. Invest.</i> 92(2):750-757 (1993). JI, et al., "Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux," <i>J. Biol. Chem.</i> 272:20982-20985 (1997).	
CL		JIAN, et al., "Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors," <i>J. Biol. Chem.</i> 273: 5599-5606 (1998).	
CL		KAPOOR, et al., "Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5," <i>J. Cell Biol.</i> 150: 975-988 (2000).	
M		KINGSLEY, et al., "Receptor-mediated endocytosis of low density lipoprotein: Somatic cell mutants define multiple genes required for express of surface-receptor activity," <i>Proc. Natl. Acad. Sci. USA</i> 81:5454-5458 (1984).	
CL		KOZARSKY, et al., "Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels," <i>Nature</i> 387:414-417 (1997).	

Examiner's Signature	V. Balasubramanian	Date Considered	2/6/06
----------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number * See attached Kinds of U.S. Patent Documents. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/681,746		
		Filing Date	October 8, 2003		
		First Named Inventor	Thomas J.F. Nieland		
		Group Art Unit			
		Examiner Name			
Sheet	4	of	5	Attorney Docket Number	MIT 9952

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
M		KOZARSKY, et al., "Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse," <i>Arterio. Thromb. Vasc. Biol.</i> 20: 721-727 (2000).	
M		KRIEGER, "Complementation of Mutations in the LDL Pathway of Receptor-Mediated Endocytosis by Cocultivation of LDL Receptor-Defective Hamster Cell Mutants", <i>Cell</i> 33: 413-422 (1983).	
M		KRIEGER, "Charting the fate of the "good cholesterol": Identification and characterization of the high-density lipoprotein receptor SR-BI," <i>Ann. Rev. Biochem.</i> 68:523-558 (1999).	
M		KRIEGER, "Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems," <i>J. Clin. Invest.</i> 108: 793-797 (2001).	
M		LENCER, et al., "Membrane traffic and the cellular uptake of cholera toxin," <i>Biochim. Biophys. Acta</i> 1450: 177-190 (1999).	
M		MARDONES, et al., "Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice," <i>J. Lipid Res.</i> 42: 170-180 (2001).	
M		MIETTINEN, et al., "Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice," <i>J. Clinical Invest.</i> 108: 1717-1722 (2001).	
M		PITAS, et al., "Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy," <i>Arteriosclerosis</i> 1: 177 (1981).	
M		RIGOTTI, et al., Regulation by adrenocorticotrophic hormone of the in vitro expression of scavenger receptor class B Type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland," <i>J. Biol. Chem.</i> 271:33545-33549 (1996).	
M		SCHAUB, et al., "Recombinant Human Macrophage Colony-Stimulating Factor Reduces Plasma Cholesterol and Carrageenan Granuloma Foam Cell Formation in Watanabe Heritable Hyperlipidemic Rabbits," <i>Arterioscler. Thromb.</i> 14(1):70-76 (1994).	

Examiner's Signature	V. Balasubramanian	Date Considered	2/6/06
----------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/681,746		
		Filing Date	October 8, 2003		
		First Named Inventor	Thomas J.F. Nieland		
		Group Art Unit			
		Examiner Name			
Sheet	5	of	5	Attorney Docket Number	MIT 9952

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
M		SPIRO, et al., "Wortmannin alters the transferrin receptor endocytic pathway in vivo and in vitro," <i>Mol. Biol. Cell.</i> 7: 355-367 (1996).	
M		STEIN, et al., "Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether," <i>Biochim. Biophys. Acta</i> , 752: 98 (1983).	
M		TEHEL, et al., "Apolipoprotein A-I is necessary for the in vivo formation of high density lipoprotein competent for scavenger receptor BI-mediated cholesteryl ester-selective uptake," <i>J. Biol. Chem.</i> 277(29): 26565-26572 (2002).	
M		TRIGATTI, et al., "Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology," <i>Proc. Nat. Acad. Sci. USA</i> 96: 9322-9327 (1999).	
M		UEDA, et al., "Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics," <i>J. Biol. Chem.</i> 275: 20368-20373 (2000).	
M		UITTENBOGAARD, et al., "Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid-protein complex," <i>J. Biol. Chem.</i> 277: 4925-4931 (2002).	

Examiner's Signature	V. Balasubramanian	Date Considered	2/6/06
----------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.